The FTC Wrote an Enforcement Policy, and It Changed the Packaging
The US Federal Trade Commission's November 2016 enforcement policy statement on homeopathic product claims — what it requires on labels, the 'competent and reliable scientific evidence' standard, and examples of the disclosure language it mandated.
Great Ormond Street. The building kept its function and changed its name in 2010.Photo: Royal London Homoeopathic Hospital, Great Ormond Street, Bloomsbury, May 2024 · Wikimedia Commons
Boxes sold in the United States have carried the Commission's wording since.Photo: Rachel Claire / Pexels
A November 2016 statement from the Federal Trade Commission established that homeopathic OTC products must meet the same evidentiary standard as any other health claim — or carry a conspicuous disclaimer.
What the Policy Said
The Federal Trade Commission published its Enforcement Policy Statement on Marketing Claims for OTC Homeopathic Products on 15 November 2016. The document addressed a long-standing inconsistency: over-the-counter homeopathic products had been marketed with efficacy claims for decades while remaining exempt, in practice, from the clinical evidence requirements applied to conventional drugs. The FTC's statement closed that gap under the agency's existing deceptive-advertising authority, without creating new regulations.
The conclusions section, where a review states its own finding rather than a summary of it.Photo: MART PRODUCTION / Pexels
The core requirement is the FTC's standard "competent and reliable scientific evidence" test — the same bar applied to any other health or efficacy claim on a consumer product. For a homeopathic preparation sold with a claim that it treats or prevents a condition, the manufacturer must possess that level of evidence before making the claim. The statement acknowledged explicitly that, for most homeopathic products, such evidence does not exist ↗.
The Disclosure Requirement
Because the FTC recognised that the market would not empty overnight, the policy provided a pathway for continued sale: products whose claims are not supported by scientific evidence may remain on shelves, but only if they carry a clear, prominent disclosure. The statement specified two acceptable disclosure formulations. The first states that there is no scientific evidence that the product works. The second states that the product's claims are based only on theories of homeopathy from the 1700s and 1800s that are not accepted by most modern medical experts.
- September 2015FTC public workshop on OTC homeopathic product claims
- 15 November 2016FTC Enforcement Policy Statement published
- 2019FDA revised its own compliance guidance on homeopathic products
Both formulations must appear conspicuously — the FTC's longstanding standard requires that disclosures not be buried in fine print or placed where a reasonable consumer would miss them. The agency noted that a disclosure tucked on a side panel, in small type, or rendered in low-contrast typography would likely fail the conspicuousness test.
The policy also addressed implied claims. A product label that prominently displays symptoms — "runny nose," "sleeplessness," "teething" — without an explicit efficacy statement can still constitute an implied claim under FTC doctrine. Such presentations fall under the same evidentiary requirement.
Labelled by remedy and by potency; what is inside each vial is sugar.Photo: cottonbro studio / Pexels
Context and Limits
The 2016 statement was a policy document, not a final rule with the force of regulation, and it did not alter the Food and Drug Administration's separate framework for homeopathic products. The FDA regulates homeopathic preparations as drugs under the Federal Food, Drug, and Cosmetic Act and had its own compliance guidance — later revised in 2019 — governing which products could be marketed without pre-approval. The FTC statement operated in parallel, governing advertising and labelling claims under Section 5 of the FTC Act, which prohibits unfair or deceptive acts in commerce.
Enforcement under the statement was complaint-driven and case-by-case, consistent with the FTC's general approach to advertising. The agency cited the Homeopathic Pharmacopoeia of the United States ↗ as the existing reference for which substances are recognised in homeopathic practice, noting that HPUS listing does not itself constitute evidence of efficacy.
The statement drew on a public workshop the FTC had convened in September 2015, at which it heard testimony from scientists, manufacturers, consumer advocates and regulators about the evidence base for homeopathic products. The 2015 workshop record and the 2016 statement together constitute the agency's primary documentary account of its reasoning.
In practical terms, the policy required manufacturers to make a binary choice: produce the clinical evidence, or label the product as resting on pre-scientific theory. Several major retailers subsequently revised their shelf placement and labelling practices in response, making the FTC's 2016 document one of the more consequential regulatory interventions in the recent commercial history of homeopathic products in the United States.